A Phase 2 interventional study of Basmisanil and Placebo in Stroke, sponsored by Hoffmann-La Roche. Terminated at 13 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-01-02.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 321 studies in Stroke with a site in Spain — 71 open to participants now, 89 under way, 6 of them phase 3. Stroke · Spain.
Among the 321 studies in Stroke with a site in Spain, this one is the 242nd largest by enrollment of the 244 interventional ones that give a count, is one of 13 that started in 2017, is one of 14 in phase 2, and was the 113th registered.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →71 of the 321 studies in Stroke with a site in Spain are open now. Recruiting first, the newest first:
Neuron, Spain · Sites in Spain
Ages 18+ · Healthy volunteers
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18–80
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain, Belgium, Germany and 3 more countries
Ages 18+
Ancor Rebassa Cabrera · Sites in Spain
Ages 18+
Dr. Yaroslav Winter · Sites in Spain, Czechia, Germany and 1 more country
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
321 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 44 · Phase 4 21
First in 1998; this study’s year is marked. 13 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 49 across 6,036 interventional studies indexed under Stroke.
Median enrollment 70 across the 244 interventional studies, 250 across the 77 observational. Of the 197 that completed or were terminated, 33 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 321 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
24 of the studies in Stroke with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06296082Phase 3Universiteit AntwerpenComparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity | 2026-12-30 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07497464Alfredo Lerín CalvoValidity of an Open-access Handedness Recognition Task in Stroke Patients | 2026-11 |
Add all 24 to your calendar (.ics) → With an account.
Among the 321 studies in Stroke with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
Drug: Basmisanil
Placebo matched to basmisanil orally twice daily for 90 days.
Drug: Placebo
Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
Also known as: RO5186582
Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
Change From Baseline in FMMS Score at Day 90
Time frame: Baseline (Day 1), Day 90
Number of Participants with Adverse Events
Time frame: Baseline (Day 1) up to 28 days after last dose of study drug (latest at Day 118)
Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Day 30
Time frame: Baseline (Day 1), Day 30
Change From Baseline in MoCA Score at Day 90
Time frame: Baseline (Day 1), Day 90
Change From Baseline in National Institute of Health Stroke Scale (NIHSS) Score At Day 3
Time frame: Baseline (Day 1), Day 3
Change From Baseline in NIHSS Score At Day 10
Time frame: Baseline (Day 1), Day 10
Change From Baseline in NIHSS Score At Day 30
Time frame: Baseline (Day 1), Day 30
Change From Baseline in NIHSS Score At Day 90
Time frame: Baseline (Day 1), Day 90
Change From Baseline in NIHSS Score At 28 Days After Last Dose
Time frame: Baseline (Day 1) and at 28 days after last dose of study drug (latest on Day 118)
Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score At Day 3
Time frame: Baseline (Day 1), Day 3
Change From Baseline in C-SSRS Score At Day 30
Time frame: Baseline (Day 1), Day 30
Change From Baseline in C-SSRS Score At Day 60
Time frame: Baseline (Day 1), Day 60
Change From Baseline in C-SSRS Score At Day 90
Time frame: Baseline (Day 1), Day 90
Change From Baseline in C-SSRS Score At 28 Days After Last Dose
Time frame: Baseline (Day 1), at 28 days after last dose of study drug (latest on Day 118)
Change From Baseline in Modified Rankin Scale (mRS) Score At Day 90
Time frame: Baseline (Day 1), Day 90
mRS Score At Day 90
Time frame: Day 90
Change From Baseline in Fugl-Meyer Assessment (FMA) Total Score at Day 90
Time frame: Baseline (Day 1), Day 90
Change From Baseline in FMA Subscale Score at Day 90
Time frame: Baseline (Day 1), Day 90
Apparent Oral Clearance (CL/F) of Basmisanil
Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3
Maximum Observed Plasma Concentration (Cmax) of Basmisanil
Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3
Apparent Volume of Distribution at Steady States (Vss) of Basmisanil
Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3
Area Under the Curve [AUC] of Basmisanil
Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3
Ran from Feb 2017 to primary completion in Nov 2017, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Basmisanil